Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,740 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer.
Mukherjee UA, Hockings H, Counsell N, Patel A, Narayanan P, Wilkinson K, Dhanda H, Robinson K, McNeish I, Anderson ARA, Miller R, Gourley C, Graham T, Lockley M. Mukherjee UA, et al. Among authors: robinson k. BMJ Open. 2024 Dec 22;14(12):e091262. doi: 10.1136/bmjopen-2024-091262. BMJ Open. 2024. PMID: 39806715 Free PMC article. Clinical Trial.
Risk Model-Guided Clinical Decision Support for Suicide Screening: A Randomized Clinical Trial.
Walsh CG, Ripperger MA, Novak L, Reale C, Anders S, Spann A, Kolli J, Robinson K, Chen Q, Isaacs D, Acosta LMY, Phibbs F, Fielstein E, Wilimitis D, Musacchio Schafer K, Hilton R, Albert D, Shelton J, Stroh J, Stead WW, Johnson KB. Walsh CG, et al. Among authors: robinson k. JAMA Netw Open. 2025 Jan 2;8(1):e2452371. doi: 10.1001/jamanetworkopen.2024.52371. JAMA Netw Open. 2025. PMID: 39752160 Free PMC article. Clinical Trial.
Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy.
Elghawy O, Barsouk A, Reed-Guy L, Stalker M, Sussman J, Robinson K, Kosteva J, Singh A, Cohen RB, Langer C, Ciunci C, D'Avella C, Sun L, Marmarelis ME, Aggarwal C. Elghawy O, et al. Among authors: robinson k. Clin Lung Cancer. 2024 Dec 13:S1525-7304(24)00263-8. doi: 10.1016/j.cllc.2024.11.014. Online ahead of print. Clin Lung Cancer. 2024. PMID: 39743378 No abstract available.
2,740 results